AOD-9604 vs tirzepatide: what the evidence actually says

Last updated 2026-07-25

What is AOD-9604 and what was it supposed to do?

AOD-9604 is a synthetic fragment of human growth hormone, built from the C-terminal 176-191 region that researchers believed controlled the fat-metabolizing (lipolytic) effect of HGH without triggering the growth-promoting or insulin-resistance side effects tied to full-length growth hormone. The idea was elegant on paper: isolate the piece of the molecule that tells fat cells to release stored fat, and leave the rest of the hormone's baggage behind. That rationale drove a real drug development program. A 2004 review in Current Opinion in Investigational Drugs covered AOD-9604's metabolic profile as an obesity candidate in development, reflecting the pharmaceutical industry's genuine interest in the fragment approach at the time ^[1]. A follow-up 2006 review of obesity drugs in clinical development kept AOD-9604 on the list of candidates being tracked through the pipeline ^[2]. The company that developed it, Metabolic Pharmaceuticals (later Calzada), ran it through Phase II human obesity trials. That's further than most peptides sold online ever get. The problem is what happened when the results came in.

Did AOD-9604 actually work for weight loss in human trials?

This is the part a lot of sellers skip, so it's worth being direct: AOD-9604's human obesity trials did not show weight loss that separated convincingly from placebo. Reviews tracking the drug's development through Phase II describe a program that stalled on efficacy, not on safety ^[1][2]. The compound was well tolerated, but tolerability was never the issue. The issue was that it didn't move the needle on body weight enough to justify an approval filing, and the sponsor's obesity program did not advance to an approved product. That's a meaningfully different outcome than 'it doesn't work at all.' The mechanism (lipolytic fragment of HGH) has support in preclinical and mechanistic literature. But the gap between 'plausible mechanism' and 'clinically meaningful weight loss in people' is exactly where AOD-9604 fell short. No FDA-approved product built on this fragment exists today [Drugs@FDA database, accessdata.fda.gov]. If you're comparing AOD-9604 to tirzepatide on the strength of human trial outcomes, this is the fact that decides the comparison before you get to dosing or cost.

What is tirzepatide and how strong is its trial evidence?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. It works through an entirely different mechanism than AOD-9604: instead of trying to isolate a fat-burning fragment of growth hormone, it amplifies incretin hormone signaling that slows gastric emptying, increases satiety, and improves insulin sensitivity. The evidence base is not close. Tirzepatide went through a full Phase III program (the SURMOUNT trials) with thousands of participants, and it holds a current FDA approval you can verify directly in the Drugs@FDA database [FDA, Drugs@FDA]. AOD-9604 never reached that bar. It stalled in Phase II with a weight-loss signal too weak to separate from placebo ^[1][2]. That's the whole comparison in one paragraph: one drug has a completed, approved, large-scale human efficacy record; the other has a stalled trial program and mechanistic plausibility. Anyone telling you they're comparable options for 'proven fat loss' is not being straight with you.

AOD-9604 vs tirzepatide: side-by-side comparison

The table makes the asymmetry obvious. These are not two similar options at different price points. They are a compound that stalled in human efficacy testing and a compound that cleared full FDA review.

Is AOD-9604 legal to buy, and how does that compare to tirzepatide?

Neither AOD-9604 nor compounded tirzepatide sits in a simple legal category, but the frameworks differ. Bulk drug substances used in 503A pharmacy compounding must appear on FDA's Bulks List under 21 CFR 216.23, and outsourcing facilities compounding under 503B follow the separate list at 21 CFR 216.24 ^[3][4]. AOD-9604 does not appear on either current FDA bulks list [FDA, bulk drug substances for 503A]. That means a compounding pharmacy legally cannot represent it as an FDA-sanctioned compounded drug ingredient the way it could for a substance actually on those lists. Tirzepatide itself is an approved drug product (Zepbound, Mounjaro), which puts it under a different regulatory track entirely, though compounded versions of tirzepatide have gone through their own separate scrutiny tied to drug shortage rules under 21 U.S.C. 353a ^[5]. That's a distinct legal question from AOD-9604's bulk-substance status, and conflating the two muddies what's actually a fairly clear-cut fact: AOD-9604 is sold in the US almost entirely as a research chemical, not a compounded pharmaceutical, and its intended use matters legally. Under 21 CFR 201.128, a product's 'intended use' is established by labeling, advertising, and how it's represented, more than by a disclaimer buried in fine print ^[6]. If a listing markets AOD-9604 for human fat loss, that intended-use standard is exactly the kind of claim FDA scrutiny cares about. If you're deciding where to source anything AOD-9604 related, that legal backdrop is why a provider-reviewed route matters more than price. AOD-9604 Co works with a provider-reviewed pathway that connects you to a fulfilling pharmacy partner rather than an unregulated research-chemical seller; AOD-9604 Co does not compound or manufacture anything itself.

Does AOD-9604 show up on a drug test the way HGH does?

No. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it wouldn't trigger a positive result on the standard test used to detect growth hormone doping ^[7]. That's a narrow, specific finding about one detection method, not a blanket statement that AOD-9604 is undetectable or unregulated in sport. Separately, anti-doping labs have developed other ways to catch small peptides like AOD-9604 in urine. A 2016 method in the Journal of Separation Science describes direct urine injection combined with liquid chromatography and ion mobility mass spectrometry specifically built to screen for peptides under 2 kDa, the size class AOD-9604 falls into ^[8]. Broader reviews of peptide detection in sports doping control describe ongoing work to catch peptidic drugs and their analogs that don't show up on older immunoassay-based tests ^[9][10]. Bottom line: AOD-9604 not triggering one specific hGH immunoassay isn't the same as it being invisible to modern anti-doping testing. Athletes under any testing authority should treat it as detectable, full stop.

Why did drug developers abandon the AOD-9604 fragment approach?

The honest answer is that the human obesity trial data wasn't good enough to carry it forward, not that the underlying biology was disproven. The 2004 and 2006 pipeline reviews describe AOD-9604 as a legitimate obesity drug candidate moving through development ^[1][2], which tells you the fragment hypothesis (isolate HGH's fat-metabolizing region, skip the growth-hormone side effects) was taken seriously by real pharmaceutical scientists, more than supplement marketers. What killed the program was efficacy, not safety. Tolerability was reportedly fine. But a Phase II obesity trial needs to show weight loss that clearly beats placebo by a clinically meaningful margin, and that's the exact result AOD-9604 didn't reliably deliver ^[1][2]. Drug development is unsentimental about that gap. A safe compound that doesn't outperform placebo gets shelved, and that's what appears to have happened here rather than any FDA approval ever materializing [Drugs@FDA database]. It's worth contrasting that with tesamorelin, another growth-hormone-axis peptide that did clear FDA approval, for HIV-associated lipodystrophy specifically. If you want to see how a related peptide fared when its trial data actually held up, the AOD-9604 vs tesamorelin comparison lays out that contrast directly.

Is AOD-9604 used for anything besides fat loss now?

Yes, and this is where the current research literature is actually more active than on the obesity side. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics, including applications, challenges, and future directions for compounds in this class ^[11]. A companion 2026 paper in Sports Medicine reviews the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[12]. These reviews reflect a real shift in where research interest sits: cartilage and joint applications, not obesity. That doesn't mean the orthopaedic use case has strong efficacy data behind it yet either; both papers are 2026 reviews summarizing an emerging and mixed evidence landscape, not confirmations that AOD-9604 works for joint repair. If you're researching AOD-9604 for reasons other than fat loss, that's a different evidence conversation than the one this article is having, and it deserves its own honest look rather than being folded into weight-loss marketing.

How do the injection schedules and practical use compare?

Both compounds are given by subcutaneous injection, but that's about where the practical similarity ends. Tirzepatide (Zepbound, Mounjaro) is dosed once weekly at FDA-labeled doses that titrate upward over months, with dosing guidance built into the approved product labeling you can check in Drugs@FDA [FDA, Drugs@FDA]. There's a standardized, tested schedule behind it. AOD-9604 protocols circulating online (daily injection, typically before meals or before bed) come from research literature and community practice, not from an FDA-approved label, because no such label exists. If you're looking at when to take AOD-9604 peptide or how to prepare it, understand you're following a research protocol, not a clinically validated dosing regimen. The reconstitution guide covers the practical steps, but no amount of correct reconstitution technique changes the underlying trial outcome question.

Which one should you actually consider, and why?

If your goal is data-backed fat loss and you can access it, tirzepatide has the stronger record by a wide margin: full Phase III trials, FDA approval, a published mechanism, and labeled dosing. That's not a close call. AOD-9604 is not nothing. The fragment hypothesis is real science, and the compound cleared safety and tolerability screening through Phase II ^[1][2]. But the human obesity efficacy data that would justify choosing it over an approved GLP-1/GIP therapy for weight loss specifically isn't there. Anyone selling AOD-9604 as a 'GLP-1 alternative' or claiming it matches tirzepatide's results is asking you to ignore the trial record. If you're researching AOD-9604 anyway, whether for its orthopaedic research angle or because you want to understand the compound before deciding it's not right for your goals, start with the AOD-9604 peptide overview for the full mechanism rundown, and if you decide to source it for research purposes, go through a provider-reviewed route rather than an unregulated seller. That's the one place AOD-9604 Co has a direct stake in this conversation: pointing you to a fulfilling pharmacy partner instead of a research-chemical storefront with no quality oversight.

Frequently asked questions

Is AOD-9604 as effective as tirzepatide for weight loss?

No. AOD-9604's human obesity trials did not show weight loss that separated convincingly from placebo, while tirzepatide produced large, sustained weight loss in full Phase III trials and holds FDA approval as Zepbound. The trial evidence strongly favors tirzepatide for anyone specifically seeking weight loss.

Why did AOD-9604 fail its obesity trials?

It wasn't a safety failure. Reviews of the drug's development describe tolerability as acceptable through Phase II, but the weight-loss effect wasn't strong or consistent enough to clearly beat placebo, which is the bar a Phase II obesity trial needs to clear to move forward toward approval.

Is AOD-9604 FDA approved?

No. AOD-9604 has no FDA-approved product listing in the Drugs@FDA database and does not appear on FDA's 503A or 503B bulk drug substances lists used for legal pharmacy compounding, unlike tirzepatide, which is approved as Zepbound and Mounjaro.

Does AOD-9604 show up on drug tests?

A 2013 study found AOD-9604 doesn't trigger the standard WADA hGH isoform immunoassay, but newer mass spectrometry methods built specifically to catch small peptides under 2 kDa can detect it. Treat it as detectable under any serious anti-doping testing program.

Can you buy AOD-9604 legally in the US?

AOD-9604 is not on FDA's approved bulks lists for pharmacy compounding, so it's typically sold as a research chemical, not a compounded drug. How it's marketed matters legally under FDA's intended-use rules; a provider-reviewed sourcing route is the more defensible path than an unregulated seller.

What is the mechanism difference between AOD-9604 and tirzepatide?

AOD-9604 is a fragment of growth hormone aimed at isolating its fat-metabolizing (lipolytic) effect. Tirzepatide is a dual GIP/GLP-1 receptor agonist that works through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. They target completely different biological pathways.

Has anyone studied combining AOD-9604 with GLP-1 drugs like tirzepatide?

No published human trial data compares or combines the two. Any protocol claiming a combined benefit from stacking AOD-9604 and tirzepatide is not backed by the trial literature currently available and should be treated as unverified until real combination-trial data exists.

Is AOD-9604 used for anything other than weight loss?

Current research interest has shifted toward orthopaedic applications. A 2026 review in JAAOS Global Research & Reviews and a companion 2026 Sports Medicine review both cover peptide therapies, including AOD-9604, for musculoskeletal and joint-related uses, separate from the obesity question.

How is tirzepatide dosed compared to AOD-9604?

Tirzepatide (Zepbound, Mounjaro) is dosed once weekly per FDA-approved labeling with a defined titration schedule. AOD-9604 protocols are typically daily subcutaneous injections based on research literature and community practice, not an FDA-approved label, since no such label exists.

Does AOD-9604 cause the same side effects as HGH?

The fragment was designed specifically to avoid HGH's growth-promoting and insulin-resistance effects while keeping the fat-metabolizing action. Trial reviews describe it as generally well tolerated through Phase II testing, though the obesity efficacy signal itself was the part that didn't hold up.

Is compounded tirzepatide the same legal category as AOD-9604?

No. Tirzepatide is an FDA-approved drug product, and compounded versions have followed a separate regulatory path tied to drug shortage rules under federal compounding law. AOD-9604 is not an approved drug and isn't on FDA's bulk substances lists for legal compounding at all.

Should I choose AOD-9604 over tirzepatide for fat loss?

Based on the trial record, no. Tirzepatide has full Phase III data and FDA approval showing significant weight loss. AOD-9604's human obesity trials stalled without a clear placebo-beating result. If weight loss is your specific goal, the evidence points toward tirzepatide, not AOD-9604.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604's metabolic profile and development as an obesity drug candidate, reflecting the fragment's lipolytic rationale
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 tracked among obesity drugs in clinical development pipeline reviews
3. eCFR, 21 CFR 216.23: The 503A Bulk Drug Substances List defines which substances pharmacies may legally use in compounding
4. eCFR, 21 CFR 216.24: The 503B Bulks List sets a separate standard for outsourcing facility compounding
5. Cornell Law, 21 U.S.C. 353a: Federal pharmacy compounding law governs compounded versions of approved drugs like tirzepatide
6. eCFR, 21 CFR 201.128: FDA's definition of intended use is established through labeling and advertising claims, not disclaimers alone
7. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay
8. PubMed, Journal of Separation Science (2016): Direct urine injection with LC and ion mobility mass spectrometry screens for peptides under 2 kDa, including compounds like AOD-9604
9. PubMed, Expert Review of Proteomics (2014): Ongoing development of methods to detect peptidic drugs and analogs in sports doping controls
10. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical approaches developed for detecting emerging non-approved therapeutics in doping controls
11. PubMed, JAAOS Global Research & Reviews (2026): Review of therapeutic peptides in orthopaedics covering applications, challenges, and future directions
12. PubMed, Sports Medicine (2026): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
13. FDA, Drugs@FDA database: Verifies FDA approval status of tirzepatide products versus absence of any AOD-9604 approved product
14. FDA, bulk drug substances used in compounding under section 503A: AOD-9604 is not among substances FDA has placed on the 503A bulk drug substances list